Rare Disease Patients Face Barriers in Access and Care
An FDA-approved medication can now treat Friedreich's ataxia, but health plan barriers and formulary exclusions keep many patients from receiving it.
Larimar started at buy by Truist on Friedreich's ataxia drug
Truist has initiated coverage of Larimar (LRMR) with a buy rating, citing an "asymmetric" risk/reward ahead of regulatory ...
pharmaphorum3d
Biogen’s Skyclarys is first EU drug for Friedreich’s ataxia
After getting a green light from the European Commission, Biogen’s Skyclarys is the first approved medicine for the inherited neurological disease Friedreich’s ataxia (FA) in the EU.
Design Therapeutics: Not A Complete Washout Despite Setback
Design Therapeutics' GeneTAC platform is revolutionizing genetic disease treatment with small molecules and promising results ...
Solid Biosciences' Ataxia Treatment Receives FDA Fast-Track Designation
Fast-track status will allow Solid Biosciences to have more frequent meetings with the FDA throughout the treatment-development process and, potentially, get the product to patients faster than would ...
Hosted on MSN1mon
What to know about nervous system disease 'ataxia'
There are many types, including cerebellar ataxia, sensory ataxia, vestibular ataxia, Friedreich’s ataxia and more general forms of hereditary ataxias. The most common symptoms of the disease ...
Optimistic Outlook on Larimar Therapeutics’ Nomlabofusp: Advancements in Clinical Trials for Adolescents with Friedreich’s Ataxia
Leerink Partners analyst Joseph Schwartz has reiterated their bullish stance on LRMR stock, giving a Buy rating on January 24.Invest with ...
Solid Biosciences Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia
Only dual route gene transfer therapy in development to treat Friedreich’s ataxia with FDA IND clearance and Fast Track designation - CHARLESTOWN, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ...
American Association of Individual Investors17d
Why Jupiter Neurosciences, Inc.’s (JUNS) Stock Is Down 59.50%
Jupiter Neurosciences, Inc.’s JUNS share price has dipped by 59.50%, which has investors questioning if this is right time to ...